Cargando…
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
BACKGROUND: The orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which currently is in a phase II-clinical trial in patients against metastatic prostate cancer, exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors. To fur...
Autores principales: | Olsson, Anders, Björk, Anders, Vallon-Christersson, Johan, Isaacs, John T, Leanderson, Tomas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885345/ https://www.ncbi.nlm.nih.gov/pubmed/20470445 http://dx.doi.org/10.1186/1476-4598-9-107 |
Ejemplares similares
-
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth
por: Deronic, Adnan, et al.
Publicado: (2016) -
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment
por: Isaacs, John T., et al.
Publicado: (2014) -
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
por: Björk, Per, et al.
Publicado: (2009) -
Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth
por: Deronic, Adnan, et al.
Publicado: (2016) -
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
por: Olsson, Anders, et al.
Publicado: (2015)